{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T14:17:40Z","timestamp":1783174660314,"version":"3.54.6"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81470848"],"award-info":[{"award-number":["81470848"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["201903010099"],"award-info":[{"award-number":["201903010099"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ejphar.2026.178917","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:16:18Z","timestamp":1777673778000},"page":"178917","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Targeted knockdown of hepatic XDH via GalNAc-siRNA alleviates hyperuricaemia and renal injury in UOX\u2212\/\u2212 mice"],"prefix":"10.1016","volume":"1025","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7133-7743","authenticated-orcid":false,"given":"Ruikai","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4614-1787","authenticated-orcid":false,"given":"Xiuqing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2026.178917_bib1","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s10616-016-0005-z","article-title":"Assay systems for screening food and natural substances that have anti-hyperuricemic activity: uric acid production in cultured hepatocytes and purine bodies-induced hyperuricemic model mice","volume":"69","author":"Adachi","year":"2017","journal-title":"Cytotechnology"},{"key":"10.1016\/j.ejphar.2026.178917_bib2","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1073\/pnas.78.11.6858","article-title":"Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis","volume":"78","author":"Ames","year":"1981","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2026.178917_bib3","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2404143","article-title":"Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia","volume":"391","author":"Ballantyne","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178917_bib4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12974-018-1175-8","article-title":"Urate inhibits microglia activation to protect neurons in an LPS-induced model of Parkinson's disease","volume":"15","author":"Bao","year":"2018","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.ejphar.2026.178917_bib5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/acps.12830","article-title":"The antioxidant uric acid and depression: clinical evidence and biological hypotheses","volume":"137","author":"Bartoli","year":"2018","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.ejphar.2026.178917_bib6","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1053\/j.ajkd.2022.04.006","article-title":"Initiation dose of allopurinol and the risk of severe cutaneous reactions in older adults with CKD: a population-based cohort study","volume":"80","author":"Bathini","year":"2022","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ejphar.2026.178917_bib7","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.bbadis.2014.05.022","article-title":"Pathophysiology of circulating xanthine oxidoreductase: new emerging roles for a multi-tasking enzyme","volume":"1842","author":"Battelli","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejphar.2026.178917_bib8","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1161\/ATVBAHA.121.316290","article-title":"N-Acetyl galactosamine targeting: paving the way for clinical application of nucleotide medicines in cardiovascular diseases","volume":"41","author":"Biessen","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejphar.2026.178917_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.101882","article-title":"Xanthine oxidoreductase: one enzyme for multiple physiological tasks","volume":"41","author":"Bortolotti","year":"2021","journal-title":"Redox Biol."},{"key":"10.1016\/j.ejphar.2026.178917_bib10","doi-asserted-by":"crossref","first-page":"11827","DOI":"10.1093\/nar\/gkaa670","article-title":"Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates","volume":"48","author":"Brown","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejphar.2026.178917_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2022.102271","article-title":"U-shaped association of uric acid to overall-cause mortality and its impact on clinical management of hyperuricemia","volume":"51","author":"Crawley","year":"2022","journal-title":"Redox Biol."},{"key":"10.1016\/j.ejphar.2026.178917_bib12","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(21)00569-9","volume":"397","author":"Dalbeth","year":"2021","journal-title":"Gout. Lancet"},{"key":"10.1016\/j.ejphar.2026.178917_bib13","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.ymthe.2020.06.015","article-title":"Delivery of oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug","volume":"28","author":"Debacker","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejphar.2026.178917_bib14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2208391","article-title":"Zilebesiran, an RNA interference therapeutic agent for hypertension","volume":"389","author":"Desai","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178917_bib15","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41392-024-01916-y","article-title":"Hyperuricemia and its related diseases: mechanisms and advances in therapy","volume":"9","author":"Du","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejphar.2026.178917_bib16","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1097\/HJH.0000000000003807","article-title":"Asymptomatic hyperuricemia: to treat or not a threat? A clinical and evidence-based approach to the management of hyperuricemia in the context of cardiovascular diseases","volume":"42","author":"Fiori","year":"2024","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ejphar.2026.178917_bib17","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"2020 American college of rheumatology guideline for the management of gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.ejphar.2026.178917_bib18","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40259-022-00549-3","article-title":"Therapeutic siRNA: state-of-The-art and future perspectives","volume":"36","author":"Friedrich","year":"2022","journal-title":"BioDrugs"},{"key":"10.1016\/j.ejphar.2026.178917_bib19","doi-asserted-by":"crossref","first-page":"E827","DOI":"10.1152\/ajpendo.00378.2020","article-title":"New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity","volume":"319","author":"Furuhashi","year":"2020","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2026.178917_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177441","article-title":"siRNA-based delivery systems: technologies, carriers, applications, and approved products","volume":"996","author":"Ghasemiyeh","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178917_bib21","doi-asserted-by":"crossref","first-page":"D784","DOI":"10.1093\/nar\/gku1166","article-title":"Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations","volume":"43","author":"Gonz\u00e1lez-Galarza","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejphar.2026.178917_bib22","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2337\/db18-1198","article-title":"Hepatocyte-specific ablation or whole-body inhibition of xanthine oxidoreductase in mice corrects obesity-induced systemic hyperuricemia without improving metabolic abnormalities","volume":"68","author":"Harmon","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2026.178917_bib23","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1253\/circj.CJ-20-0406","article-title":"Uric acid as a risk factor for chronic kidney disease and cardiovascular disease - Japanese guideline on the management of asymptomatic hyperuricemia","volume":"85","author":"Hisatome","year":"2021","journal-title":"Circ. J."},{"key":"10.1016\/j.ejphar.2026.178917_bib24","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1080\/17425255.2023.2287477","article-title":"Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout","volume":"19","author":"Hou","year":"2023","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ejphar.2026.178917_bib25","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41572-024-00542-w","article-title":"Tumour lysis syndrome","volume":"10","author":"Howard","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ejphar.2026.178917_bib26","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s41587-023-02105-y","article-title":"RNA interference in the era of nucleic acid therapeutics","volume":"42","author":"Jadhav","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejphar.2026.178917_bib27","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13937","article-title":"Global burden of gout in 1990-2019: a systematic analysis of the global burden of disease study 2019","volume":"53","author":"Jeong","year":"2023","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2026.178917_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/ph11020051","article-title":"Side effects and interactions of the xanthine oxidase inhibitor febuxostat","volume":"11","author":"Jordan","year":"2018","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejphar.2026.178917_bib29","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/s41440-024-02031-9","article-title":"Current updates and future perspectives in uric acid research, 2024","volume":"48","author":"Kuwabara","year":"2025","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.ejphar.2026.178917_bib30","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1038\/s41440-023-01273-3","article-title":"Update in uric acid, hypertension, and cardiovascular diseases","volume":"46","author":"Kuwabara","year":"2023","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.ejphar.2026.178917_bib31","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","article-title":"Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial","volume":"396","author":"Mackenzie","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2026.178917_bib32","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev-physiol-021113-170343","article-title":"The molecular physiology of uric acid homeostasis","volume":"77","author":"Mandal","year":"2015","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.ejphar.2026.178917_bib33","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1124\/dmd.121.000428","article-title":"The nonclinical disposition and pharmacokinetic\/pharmacodynamic properties of N-Acetylgalactosamine-Conjugated small interfering RNA are highly predictable and build confidence in translation to human","volume":"50","author":"McDougall","year":"2022","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejphar.2026.178917_bib34","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1186\/s12951-024-03004-3","article-title":"Advanced siRNA delivery in combating hepatitis B virus: mechanistic insights and recent updates","volume":"22","author":"Nguyen","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ejphar.2026.178917_bib35","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa2415818","article-title":"Lepodisiran - a long-duration small interfering RNA targeting lipoprotein(a)","volume":"392","author":"Nissen","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178917_bib36","article-title":"Comparative effectiveness of allopurinol and febuxostat in gout management","volume":"1","author":"O'Dell","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.ejphar.2026.178917_bib37","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1053\/j.ajkd.2025.04.020","article-title":"Gout management in patients with CKD: a review","volume":"86","author":"Ostrowski","year":"2025","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ejphar.2026.178917_bib38","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/00325481.2024.2377952","article-title":"Uric acid and cardiovascular diseases: a reappraisal","volume":"136","author":"Prabhakar","year":"2024","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.ejphar.2026.178917_bib39","first-page":"1","article-title":"GalNac-siRNA conjugate delivery technology promotes the treatment of typical chronic liver diseases","author":"Qin","year":"2025","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejphar.2026.178917_bib40","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178917_bib41","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejphar.2026.178917_bib42","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa2404147","article-title":"Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia","volume":"391","author":"Rosenson","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178917_bib43","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11427-018-9438-y","article-title":"siRNA therapeutics: a clinical reality","volume":"63","author":"Saw","year":"2020","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.ejphar.2026.178917_bib44","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41584-023-01006-3","article-title":"Mechanisms and rationale for uricase use in patients with gout","volume":"19","author":"Schlesinger","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ejphar.2026.178917_bib45","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrrheum.2015.132","article-title":"Allopurinol hypersensitivity: investigating the cause and minimizing the risk","volume":"12","author":"Stamp","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ejphar.2026.178917_bib46","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2205416","article-title":"Fazirsiran for liver disease associated with Alpha(1)-Antitrypsin deficiency","volume":"387","author":"Strnad","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178917_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16070938","article-title":"Targeting liver xor by GalNAc-siRNA is an effective strategy for hyperuricemia therapy","volume":"16","author":"Sun","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejphar.2026.178917_bib48","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185x.70375","article-title":"2024 update of Chinese guidelines for diagnosis and treatment of hyperuricemia and gout part I: recommendations for general patients","volume":"28","author":"Sun","year":"2025","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.ejphar.2026.178917_bib49","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s40265-023-01944-y","article-title":"Emerging urate-lowering drugs and pharmacologic treatment strategies for gout: a narrative review","volume":"83","author":"Terkeltaub","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2026.178917_bib50","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41431-022-01180-0","article-title":"Dutch pharmacogenetics working group guideline for the gene-drug interaction of ABCG2, HLA-B and allopurinol, and MTHFR, folic acid and methotrexate","volume":"32","author":"van der Pol","year":"2024","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.ejphar.2026.178917_bib51","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s11906-024-01295-3","article-title":"Hyperuricemia: an intriguing connection to metabolic syndrome, diabetes, kidney disease, and hypertension","volume":"26","author":"Vareldzis","year":"2024","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.ejphar.2026.178917_bib52","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178917_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.115073","article-title":"RNAi therapies: expanding applications for extrahepatic diseases and overcoming delivery challenges","volume":"201","author":"Won Lee","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejphar.2026.178917_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22179221","article-title":"Molecular biological and clinical understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic syndrome, cardiovascular diseases and chronic kidney disease","volume":"22","author":"Yanai","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2026.178917_bib55","article-title":"Allopurinol hypersensitivity syndrome","volume":"195","author":"Yaseen","year":"2023","journal-title":"CMAJ (Can. Med. Assoc. J.)"},{"key":"10.1016\/j.ejphar.2026.178917_bib56","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann. Rheum. Dis."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926003997?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926003997?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T13:31:33Z","timestamp":1783171893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299926003997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":56,"alternative-id":["S0014299926003997"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178917","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted knockdown of hepatic XDH via GalNAc-siRNA alleviates hyperuricaemia and renal injury in UOX\u2212\/\u2212 mice","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178917","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"178917"}}